CRSP Q2 EPS Estimate Reduced by Brookline Capital Management

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at Brookline Capital Management cut their Q2 2025 earnings estimates for shares of CRISPR Therapeutics in a research report issued on Tuesday, May 6th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($1.23) per share for the quarter, down from their prior forecast of ($0.86). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($5.31) EPS, FY2026 earnings at $2.55 EPS, FY2027 earnings at $4.70 EPS, FY2028 earnings at $8.73 EPS and FY2029 earnings at $43.19 EPS.

A number of other brokerages also recently issued reports on CRSP. JMP Securities restated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Citigroup lowered their price objective on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research report on Tuesday, February 18th. Morgan Stanley lifted their target price on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a report on Friday, February 14th. Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average target price of $71.75.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $35.62 on Friday. The stock’s 50 day moving average is $38.15 and its 200 day moving average is $42.75. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $67.88. The firm has a market cap of $3.08 billion, a P/E ratio of -8.15 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. The business’s revenue was up 71.6% on a year-over-year basis. During the same period last year, the company earned ($1.43) EPS.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CRSP. Wilmington Savings Fund Society FSB bought a new position in CRISPR Therapeutics during the third quarter valued at about $40,000. Nordea Investment Management AB grew its position in shares of CRISPR Therapeutics by 4.4% during the 4th quarter. Nordea Investment Management AB now owns 125,400 shares of the company’s stock valued at $4,913,000 after acquiring an additional 5,300 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of CRISPR Therapeutics by 19.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 36,139 shares of the company’s stock worth $1,422,000 after purchasing an additional 5,898 shares during the last quarter. Highline Wealth Partners LLC bought a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $39,000. Finally, Green Alpha Advisors LLC lifted its stake in CRISPR Therapeutics by 28.6% in the fourth quarter. Green Alpha Advisors LLC now owns 24,629 shares of the company’s stock valued at $969,000 after purchasing an additional 5,471 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 9,973 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $423,054.66. Following the completion of the sale, the chief executive officer now owns 180,890 shares in the company, valued at $7,673,353.80. This represents a 5.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel James R. Kasinger sold 2,850 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the transaction, the general counsel now directly owns 77,530 shares in the company, valued at $3,288,822.60. The trade was a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock valued at $1,608,243 over the last 90 days. Insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.